Filtered By:
Condition: Atrial Fibrillation
Management: National Institute for Health and Clinical Excelle

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 31 results found since Jan 2013.

NICE approves new oral anti-coagulant for atrial fibrillation
The drug edoxaban has been given the official seal of approval for NHS use in preventing stroke and blood clots in patients with a common heart disorder.
Source: Nursing Times Breaking News - September 24, 2015 Category: Nursing Source Type: news

Editorial Time for action on atrial fibrillation
The incidence of atrial fibrillation, a common and treatable risk factor for ischaemic stroke, is predicted to increase in the coming decades, elevating the status of this arrhythmia to that of a public health priority. The growing importance of this condition is reflected by the publication in July, 2015, of two documents: the research report for the Future of Anticoagulation Initiative on the future of atrial fibrillation management in Europe; and the UK National Institute for Health and Care Excellence (NICE) Quality Standard on the treatment and management of atrial fibrillation.
Source: Lancet Neurology - August 10, 2015 Category: Neurology Authors: The Lancet Neurology Tags: Editorial Source Type: research

Aspirin too risky for stroke patients, NICE says
Adults with atrial fibrillation (AF) should no longer be prescribed aspirin to prevent stroke, NICE guidance released today said Hide related content:  Show related content read more
Source: Management in Practice - July 10, 2015 Category: Practice Management Authors: ltrevallion Tags: *** Editor ' s Pick Latest News Source Type: news

The Move Towards Full Implementation Of The Nice Guidelines For Stroke Prevention In Atrial Fibrillation: The Potential Cost And Clinical Impact
Updated treatment guidelines for atrial fibrillation (AF) have been released by the National Institute for Health and Care Excellence (NICE) in the United Kingdom and highlight a current shortfall in the prescribing of anticoagulants to patients with AF despite the importance of stroke prevention. A model was designed for use as a planning tool for Clinical Commissioning Groups (CCGs) looking to budget for the future move towards full implementation of the NICE guidelines.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: G.E. Shields, A.M. Chapman Source Type: research

NICE advises against aspirin for cutting stroke risk in AF patients
The National Institute for Health and Care Excellence has recommended that people with atrial fibrillation are prescribed an anticoagulant instead of aspirin to reduce their risk of stroke.
Source: Nursing Times Breaking News - June 20, 2014 Category: Nursing Source Type: news

GPs to review aspirin use in atrial fibrillation patients
NICE calls for increased uptake of anticoagulantsRelated items from OnMedicaAlteplase use linked to reduction in disability after strokeGPs should screen over 65s for atrial fibrillationAtrial fibrillation raises risk of cognitive problems Statin use after stroke not linked to bleedsNew guidance to prevent strokes
Source: OnMedica Latest News - June 19, 2014 Category: UK Health Source Type: news

RPS responds to NICE Guideline on Atrial Fibrillation
Responding to new guidance from NICE on how best to treat people at serious risk of a stroke because of an abnormal heart rhythm, known as atrial fibrillation (AF), Helen Williams, Consultant Pharmacist and RPS spokesperson on ca
Source: Royal Pharmaceutical Society News - June 17, 2014 Category: Drugs & Pharmacology Source Type: news

Supporting the commissioning of anticoagulation therapy for adults
This resource supports commissioners to review how anticoagulation therapy is currently initiated, provided, monitored and reviewed in their local area with particular consideration to the introduction of the novel oral anticoagulants. NICE recommendations for rivaroxaban, dabigatran and apixaban for stroke prevention in people with atrial fibrillation and rivaroxaban for treatment of deep vein thrombosis provide people who have these conditions with more choices of medication. This will have an impact on the commissioning of anticoagulation services at a local level, with an anticipated reduction in vitamin K antagonist monitoring services.
Source: NHS Networks - May 23, 2013 Category: UK Health Authors: Maria Axford Source Type: news

New stroke prevention treatment recommended by NICE
Atrial fibrillation (AF) is the most common cause of irregular heart beat. It can cause the heart rhythm to become disorganised, and on occasion too fast, leading to the inefficient pumping of blood around the body.
Source: NHS Networks - February 28, 2013 Category: UK Health Authors: Karen Topping Source Type: news

NICE costing statement for its guidance on apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation (TA 275)
Source: NICE Area: News NICE has published a costing statement to accompany its guidance on the use of apixaban for preventing stroke and systemic embolism in nonvalvular atrial fibrillation (TA 275).   The statement notes that "Apixaban provides an alternative treatment option at a comparable cost and therefore it is anticipated that there will not be a significant cost impact as a result of implementing this guidance."
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news

NICE issues final guidance supporting the use of apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation (TA 275)
Source: NICE Area: Evidence > Guidelines NICE has issued final guidance (TA 275) supporting the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with 1 or more risk factors such as:   . prior stroke or transient ischaemic attack . age 75 years or older . hypertension . diabetes mellitus . symptomatic heart failure.   NICE notes that the decision about whether to start treatment with apixaban should be made after an informed discussion between the clinici...
Source: NeLM - Cardiovascular Medicine - February 27, 2013 Category: Cardiology Source Type: news

NICE Final Appraisal Determination on ELIQUIS®
Bristol-Myers Squibb and Pfizer Ltd. have announced that the National Institute for Health and Clinical Excellence (NICE) has issued a fast-tracked Final Appraisal Determination (FAD) recommending the oral anticoagulant Eliquis (apixaban) as an option for preventing stroke and systemic embolism, in patients with non-valvular atrial fibrillation (AF) with one or more risk factors.
Source: Pharmacy Europe - January 24, 2013 Category: Drugs & Pharmacology Source Type: news

NICE issues final appraisal determination on apixaban for prevention of stroke and systemic embolism in non-valvular atrial fibrillation
Source: NICE Area: News In its final appraisal determination (FAD), NICE has supported the use of apixaban as an option for preventing stroke and systemic embolism within its marketing authorisation, that is, in people with nonvalvular atrial fibrillation with one or more risk factors (prior stroke or ischaemic attack, age 75 years or older, hypertension, diabetes mellitus or symptomatic heart failure).   The appeal period for this appraisal will close on 6 February 2013.
Source: NeLM - Cardiovascular Medicine - January 23, 2013 Category: Cardiology Source Type: news

NICE guidance supports new blood pressure device that can detect atrial fibrillation
The guidance backs use of WatchBP Home A, which could reduce the incidence of atrial fibrillation-related stroke by improving early detection. The guidance also recommends that WatchBP Home A should be considered for use in people with suspected hypertension (high blood pressure) or those being screened for hypertension in primary care.
Source: NHS Networks - January 21, 2013 Category: UK Health Authors: Maria Axford Source Type: news

Watchdog Backs AF Blood Pressure Device
Detection and treatment of dangerous atrial fibrillation is vital A new blood pressure measuring device that can also detect a dangerous heart condition has been backed by the health watchdog. New guidance from the National Institute for Clinical Excellence (NICE) supports the use of the 'WatchBP Home A' device by healthcare professionals in primary care to opportunistically detect atrial fibrillation (AF) during measurement of blood pressure. AF is one of the most common types of abnormal heart rhythm and a major cause of stroke if left untreated...
Source: Health News from Medical News Today - January 18, 2013 Category: Consumer Health News Tags: Hypertension Source Type: news